PRO 140 by IV Administration in Adults With HIV-1 Infection
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is:
1. To assess and characterize the PK and PD of PRO 140 administered IV
2. To assess the antiviral activity of PRO 140
3. To assess the safety and tolerability of PRO 140
Phase:
Phase 2
Details
Lead Sponsor:
CytoDyn, Inc.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
HIV Antibodies Leronlimab PRO-140 monoclonal antibody